Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients

A Jayaprakash Patil1,2,3, Ashish Sharma1,4, M Cristina Kenney1, Baruch D Kuppermann11Department of Ophthalmology, Gavin S Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA; 2Department of Ophthalmology, Summa Health System, Akron, OH, USA; 3Northeastern Ohio Universities Colle...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	A Jayaprakash Patil, Ashish Sharma, M Cristina Kenney, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/eabd78cadbad42678332cb969f05b9b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eabd78cadbad42678332cb969f05b9b2
record_format	dspace
spelling	oai:doaj.org-article:eabd78cadbad42678332cb969f05b9b22021-12-02T01:27:19ZValganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients1177-54671177-5483https://doaj.org/article/eabd78cadbad42678332cb969f05b9b22010-03-01T00:00:00Zhttp://www.dovepress.com/valganciclovir-in-the-treatment-of-cytomegalovirus-retinitis-in-hiv-in-a4021https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483A Jayaprakash Patil1,2,3, Ashish Sharma1,4, M Cristina Kenney1, Baruch D Kuppermann11Department of Ophthalmology, Gavin S Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA; 2Department of Ophthalmology, Summa Health System, Akron, OH, USA; 3Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH, USA; 4Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USAAbstract: Oral valganciclovir is a new and highly efficacious alternative to the chronic administration of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in HIV-infected patients. In addition to its excellent bioavailability and favorable pharmacokinetic profile, valganciclovir has also proved cost effective and is the most widely used drug in the armamentarium for the treatment of CMV retinitis. Valganciclovir is a prodrug of ganciclovir, the erstwhile commonly used therapy. In March 2001, the US Food and Drug Administration approved valganciclovir for the induction and maintenance treatment of CMV disease, including CMV retinitis. Valganciclvoir has compared favorably with both oral and intravenous treatments for induction and maintenance therapy with ganciclovir. The reduced pill burden and the ease of oral administration has helped avoid the risks associated with intravenous therapy. The most serious adverse event is neutropenia, which makes the patient susceptible to infections. In the current review, we have compiled all the available evidence-based information on valganciclovir.Keywords: CMV retinitis, ganciclovir, valganciclovir A Jayaprakash PatilAshish SharmaM Cristina Kenneyet alDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2010, Iss default, Pp 111-119 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 A Jayaprakash Patil Ashish Sharma M Cristina Kenney et al Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
description	A Jayaprakash Patil1,2,3, Ashish Sharma1,4, M Cristina Kenney1, Baruch D Kuppermann11Department of Ophthalmology, Gavin S Herbert Eye Institute, University of California, Irvine, Irvine, CA, USA; 2Department of Ophthalmology, Summa Health System, Akron, OH, USA; 3Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH, USA; 4Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USAAbstract: Oral valganciclovir is a new and highly efficacious alternative to the chronic administration of ganciclovir in the treatment of cytomegalovirus (CMV) retinitis in HIV-infected patients. In addition to its excellent bioavailability and favorable pharmacokinetic profile, valganciclovir has also proved cost effective and is the most widely used drug in the armamentarium for the treatment of CMV retinitis. Valganciclovir is a prodrug of ganciclovir, the erstwhile commonly used therapy. In March 2001, the US Food and Drug Administration approved valganciclovir for the induction and maintenance treatment of CMV disease, including CMV retinitis. Valganciclvoir has compared favorably with both oral and intravenous treatments for induction and maintenance therapy with ganciclovir. The reduced pill burden and the ease of oral administration has helped avoid the risks associated with intravenous therapy. The most serious adverse event is neutropenia, which makes the patient susceptible to infections. In the current review, we have compiled all the available evidence-based information on valganciclovir.Keywords: CMV retinitis, ganciclovir, valganciclovir
format	article
author	A Jayaprakash Patil Ashish Sharma M Cristina Kenney et al
author_facet	A Jayaprakash Patil Ashish Sharma M Cristina Kenney et al
author_sort	A Jayaprakash Patil
title	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
title_short	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
title_full	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
title_fullStr	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
title_full_unstemmed	Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients
title_sort	valganciclovir in the treatment of cytomegalovirus retinitis in hiv-infected patients
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/eabd78cadbad42678332cb969f05b9b2
work_keys_str_mv	AT ajayaprakashpatil valganciclovirinthetreatmentofcytomegalovirusretinitisinhivinfectedpatients AT ashishsharma valganciclovirinthetreatmentofcytomegalovirusretinitisinhivinfectedpatients AT mcristinakenney valganciclovirinthetreatmentofcytomegalovirusretinitisinhivinfectedpatients AT etal valganciclovirinthetreatmentofcytomegalovirusretinitisinhivinfectedpatients
_version_	1718403108756783104

Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients

Ejemplares similares